Chronic Lymphocytic Leukemia | Specialty

Dr. Ferrajoli on Treatment of Elderly Patients With CLL

October 22nd 2015

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia.

Emerging Treatments for Chronic Lymphocytic Leukemia

October 20th 2015

Utilizing Maintenance Therapy for Chronic Lymphocytic Leukemia

October 20th 2015

Therapeutic Combinations and Sequences for CLL

October 20th 2015

Using BCR-Targeted Agents for Relapsed/Refractory CLL

October 20th 2015

Anti-CD20 Antibodies for Chronic Lymphocytic Leukemia

October 20th 2015

Ongoing Role of Transplant in Chronic Lymphocytic Leukemia

October 20th 2015

Minimal Residual Disease in Chronic Lymphocytic Leukemia

October 20th 2015

Treating Younger and Older Patients With CLL

October 20th 2015

Initiating Therapy for Chronic Lymphocytic Leukemia

October 20th 2015

Dr. Shpall on Therapeutic Agents for the Treatment of CLL

October 20th 2015

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Byrd Discusses Optimizing Ibrutinib and Idelalisib in CLL

October 20th 2015

John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib and idelalisib in chronic lymphocytic leukemia, as well as unanswered questions and challenges concerning these novel agents.

Long-Term Ibrutinib Data Show Durable Responses in Untreated and Relapsed/Refractory CLL

September 23rd 2015

Patients with untreated or relapsed/refractory chronic lymphocytic leukemia achieved durable responses with single-agent ibrutinib (Imbruvica).

FDA Grants Priority Review to Maintenance Ofatumumab in CLL

September 21st 2015

The FDA has granted a priority review designation to ofatumumab as a maintenance therapy for patients with relapsed chronic lymphocytic leukemia following a response to second- or third-line therapy.

Age, Health, Risk Define Treatment Groups and Options in CLL

September 18th 2015

Fitness, age, and disease risk status form the basis for decision-making about first-line therapy for chronic lymphocytic leukemia.

FDA Approval Sought for Frontline Ibrutinib in CLL

September 14th 2015

A supplemental new drug application has been submitted for the BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia who are over the age of 65.

Dr. Chanan-Khan on Ibrutinib as Backbone of Treatment for CLL

August 25th 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).

Stephenson Cancer Center Aims for NCI Designation

August 21st 2015

Brentuximab Vedotin Label Expanded, Top-Line Results for CLL, NSCLC, and More

August 21st 2015

Venetoclax Achieves Primary Endpoint in Pivotal Phase II CLL Study

August 12th 2015

Treatment with single-agent venetoclax has met the primary endpoint of a pivotal phase II study for patients with relapsed or refractory chronic lymphocytic leukemia harboring the 17p deletion.